CYBERMED LIFE - ORGANIC  & NATURAL LIVING

EXERCISE

Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial📎

Written by CYBERMED LIFE NEWS
Attachments:
Download this file (Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis - a randomized clinical trial..pdf)Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis - a randomized clinical trial..pdf[Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial.]234 kB
facebook Share on Facebook
Abstract Title:

Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial.

Abstract Source:

Am J Clin Nutr. 2015 Mar ;101(3):487-95. Epub 2015 Jan 14. PMID: 25733633

Abstract Author(s):

Anja Mähler, Jochen Steiniger, Markus Bock, Lars Klug, Nadine Parreidt, Mario Lorenz, Benno F Zimmermann, Alexander Krannich, Friedemann Paul, Michael Boschmann

Article Affiliation:

Anja Mähler

Abstract:

BACKGROUND: Muscle weakness and fatigue are common symptoms in multiple sclerosis (MS). Green tea catechins such as (-)epigallocatechin-3-gallate (EGCG) are known to improve energy metabolism at rest and during exercise.

OBJECTIVE: We tested the hypothesis that EGCG improves energy metabolism and substrate utilization in patients with MS.

DESIGN: Eighteen patients (8 men) with relapsing-remitting MS (expanded disability status scale score<4.5, all receiving glatiramer acetate) participated in this randomized, double-blind, placebo-controlled, crossover trial at a clinical research center. All patients received EGCG (600 mg/d) and placebo over 12 wk (4-wk washout in between). After each intervention, fasting and postprandial energy expenditure (EE), as well as fat oxidation (FAOx) and carbohydrate oxidation (CHOx) rates, were measured either at rest or during 40 min of exercise (0.5 W/kg). At rest, blood samples and microdialysates from adipose tissue and skeletal muscle were also taken.

RESULTS: At rest, postprandial EE and CHOx, as well as adipose tissue perfusion and glucose supply, were significantly lower in men but higher in women receiving EGCG compared with placebo. During exercise, postprandial EE was lower after EGCG than after placebo, indicating an increased working efficiency (men>women). After placebo, exercise EE was mainly fueled by FAOx in both men and women. After EGCG, there was a shift to a higher and more stable CHOx during exercise in men but not in women.

CONCLUSIONS: Our data indicate that EGCG given to patients with MS over 12 wk improves muscle metabolism during moderate exercise to a greater extent in men than in women, possibly because of sex-specific effects on autonomic and endocrine control.


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.